Evaluation of the effectiveness of two formulations of hyaluronic acid for knee osteoarthritis.

Rihab Muhammad; Dania Mustafa; Julinar Mohamed; Rawia Zayed

doi:10.32947/ajps.v25i5.1252

Authors

Rihab Muhammad Pharmacology and Toxicology department, College of pharmacy, Mustansiriya University, Baghdad, Iraq
Dania Mustafa Baghdad Health Directorate / Al-Karkh Branch / Al-Yarmouk Teaching Hospital, Baghdad, Iraq
Julinar Mohamed Baghdad Health Directorate / Al-Karkh Branch / Al-Yarmouk Teaching Hospital, Baghdad, Iraq
Rawia Zayed Pharmacognosy department, faculty of pharmacy, zagazig University, Egypt

DOI:

https://doi.org/10.32947/ajps.v25i5.1252

Keywords:

hyaluronic acid, knee osteoarthritis, various formulations, cost-Effectiveness

Abstract

Hyaluronic acid, also known as hyaluronan, is a hydrophilic, negatively charged extracellular matrix ofglycosaminoglycan polymer with liable to change molecular weight that control its physiological role, rheological properties and uses. The main goal is to measure the effectiveness and the range of side effects of two different forms of hyaluronic acid, in patients with knee osteoarthritis. in this particular controlled, randomized, collateral group study, 30 patients , which are confirm to be suffering of knee OA with an intense pain discomfort ,all were assigned randomly to receive one of the two formulation of HA under the study cross- linked hylornic acid + mannitol and natural hyaluronan. Symptoms and function parameters were assessed after injection . At the terminal stage of the treatment, both of the candidates and specialist general evaluations were taken into consideration.In this study, we note that the two injections of HA have a clear effect on pain ,stiffness and physical function of patients after injecting HA, yet once comparing the both of HA ,it was noticeable that no difference in their effect on patients, meaning that both injections of HA are effective, but the relative difference between them is the cost and also the number of doses in the course , as the Monvisc injection, the cost of one injection is 330k IQD, and 3 doses must be taken in the course, i.e. the total is 990k IQD, while Arthromac needs single injection, and the cost is 240k IQD. As a Conclusion it was concluded that the effectiveness of IA injections of HMW-HA in various formulations is about similar, while some may be chosen over others depending on the brand, the treating physician, the price, and the total number of injections. Regarding safety, hyaluronic acid is generally considered to be safe.

References

1- Braga L, Benner J, Nelson E. Description of individual radiographic characteristics of hip OA in African American and White male and female: the Johnston County Osteoarthritis Project. Arthritis Care & Research. 2010;62(2):190–197.

2- Baqer M, Mohammed M & Jassim N. (2020). Curcumin as an additional remedy to Meloxicam in the management of patients suffering from knee OA; Evaluation of antioxidant activity. Al Mustansiriyah Journal of Pharmaceutical Sciences, 20(1), 71–81.

3- Hannah Ritchie, Lucas Rodés-Guirao, Edouard Mathieu, Marcel Gerber, Esteban Ortiz-Ospina, Joe Hasell and Max Roser (2023) - “Population Growth” Published online at OurWorldinData.org. Retrieved from: 'https://ourworldindata.org/population-growth' [Online Resource]

4- Long H, Liu Q, Yin H, et al. Prevalence trends of site-specific OA during the years of 1990 and 2019: findings from the International Burden of Disease study 2019. Arthritis Rheum. Published online March 2, 2022. doi:10.1002/art.42089

5- Epidemiology of Osteoarthritis Zhang, Yuqing et al.Clinics in Geriatric Medicine, Volume 26, Issue 3, 355 – 369

6- I Haq, E Murphy, J Dacre, Osteoarthritis, Postgraduate Medical Journal, July 2003, Volume 79, Issue 933, Pages 377–383

7- Berenbaum F, Wallace IJ, Lieberman DE, Felson DT. Modern-day environmental reasons in the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2018 Nov;14(11):674-681.

8- Delaware Valley Pain & Spine Institute.online: https://dvpainandspine.com/resting-for-pain

9- Hanada M, Takahashi M, Furuhashi H, Koyama H, Matsuyama Y. Elevated erythrocyte sedimentation rate and high-sensitivity C-reactive protein in osteoarthritis of the knee: relationship with clinical findings and radiographic severity. Annals of Clinical Biochemistry. 2016;53(5):548-553. doi:10.1177/0004563215610142

10- Altman R, Bedi A, Manjoo A, Niazi F, Shaw P, Mease P. Anti-Inflammatory Effects of Intra-Articular Hyaluronic Acid: A Systematic Review. CARTILAGE. 2019;10(1):43-52. doi:10.1177/1947603517749919

11- Gupta RC, Lall R, Srivastava A, Sinha A: Hyaluronic Acid: Molecular Mechanisms and Therapeutic Trajectory. Front Vet Sci. 2019 Jun 25; 6:192. doi: 10.3389/fvets.

12- Carmen G. Boeriu, Jan Springer, Floor K. Kooy, Lambertus A. M. van den Broek, and Gerrit Eggink, "Production Procedures for Hyaluronan," International Journal of Carbohydrate Chemistry, vol. 2013, Article ID 624967, 14 pages.

13- Kendra Walker; Brandon M. Basehore; Amandeep Goyal; Patrick M. Zito. Hyaluronic Acid:National Library of medicine; StatPearls: July 3, 2023

14- Sillo O, Jackson k, Lopez L, Thomas E, Suhail A: WOMAC Osteoarthritis Index, physiopedia July 2013.

15- American College of Rheumatology. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). https://www.physio-pedia.com/WOMAC_Osteoarthritis_Index

16- S. S., E. (2011). The impact of chloroquine phosphate on C-reactive protein and ESR value in patients with knee OA. Al Mustansiriyah Journal of Pharmaceutical Sciences, 10(2), 1–8

17- Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation as a therapy for knee OA. Cochrane Database Syst Rev. 2006;(2):CD005321.

18- Ishijima M, Nakamura T, Shimizu K, Hayashi K, Kikuchi H, Soen S, Omori G, Yamashita T, Uchio Y, Chiba J, et al. comparasion between Intra articular hyaluronic acid injection and oral NSAID preparation in the therapy of knee OA. a multi-center, randomized, open-label, non-inferiority trial. Arthritis Res Ther. 2014;16(1): R18.

19- Raynauld JP, Torrance GW, Band PA, Goldsmith CH, Tugwell P, Walker V, Schultz M, Bellamy N. A prospective, randomized, pragmatic, health results trial estimating the incorporation of hylan G-F 20 into the treatment pattern administered for patients suffering from knee OA (part 1 of 2): clinical results. Osteoarthr Cartil. 2002;10(7):506–517

20- Kahan A, Lleu PL, Salin L. Prospective randomized experiment assessing the medicoeconomic benefits of Hylan GF-20 versus traditional therapy in knee OA. Joint Bone Spine. 2003;70(4):276–281.

21- Bodnár, Magdolna & Daróczi, Lajos & Batta, Gyula & Bako, Jozsef & Hartmann, John & Borbély, János. (2009). Preparation and characterization of cross-linked hyaluronan nanoparticles. Colloid and Polymer Science. 287. 991-1000. 10.1007/s00396-009-2061-9.

22- Reid, M.C. Viscosupplementation for Osteoarthritis: a Primer for Primary Care Physicians. Adv Ther 30, 967–986 (2013). https://doi.org/10.1007/s12325-013-0068-6.

23- Thabane L, Mbuagbaw L, Zhang S, Samaan Z, Marcucci M, Ye C, Thabane M, Giangregorio L, Dennis B, Kosa D, et al. A tutorial on sensitivity analyses in clinical trials: the what, why, when and how. BMC Med Res Methodol. 2013; 13:92.

24- Roos EM, Roos HP, Lohmander LS, Ekdahl C, Beynnon BD. Knee damage and osteoarthritis results grade (KOOS)- improvement of a self-administered result. J Orthop Sports Phys Ther. 1998;28(2):88–96.